Providing distributed blockchain verification services and solutions consulting.

Selah Partners is a management consulting firm that supports companies and investors to create lasting value.

Liberty Fellowship seeks to promote outstanding leadership in South Carolina, empowering the state and its future leaders to realize their full potential. Our mission is to offer South Carolina’s next generation of leaders the opportunity to explore the values that sustain them; cultivate respect for both the ideas and beliefs of others; and become significant contributors to our state, and to society at large.

Michael Bolick led a second management buyout of Selah, this time from EKF, in December 2015.

Following his sale of Selah Genomics to EKF in April 2014, Michael served EKF as CEO.

Following management buyout of Lab21 Inc and subsequent co-founding of Selah Genomics in December 2012, Michael served as Chairman & CEO.Selah Genomics is a personalized medicine diagnostic specialist supporting healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. Selah delivers a rapidly growing portfolio of advanced diagnostic tests, focused initially towards oncology and infectious disease. Selah’s services add value to early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry and helps clinicians and healthcare providers treat and monitor patients, thereby improving patient outcomes.Michael sold Selah Genomics to EKF Diagnostics, a multinational diagnostics firm based in Cardiff UK, in April 2014.

Following his sale of Selah Technologies to Lab21 Ltd in December 2009, Michael served as President of Lab21 Inc, Lab21's resulting wholly owned US subsidiary. Lab21 is a rapidly growing healthcare diagnostics business. The company’s vision is of providing personalised diagnostic testing for disease identification, disease predisposition and personalised medicine to protect people from the health problems of tomorrow. We believe that ‘prevention is better than cure’ and aim to provide information that helps to protect people from their health problems of tomorrow.In December 2012, Michael led a management buyout of Lab21 Inc and co-founded Selah Genomics with Ken Morgan and Jeremy Stuart.

SCBIO is a member organization that exists to support and advance South Carolina’s life science industry through collaboration, advocacy, workforce development, and support for business operations. This mission furthers our goal of ensuring that South Carolina’s companies, research institutions, and citizens reap the economic and societal benefits of a world-class life sciences cluster.

Michael founded Selah Technologies in June 2006. Selah Technologies is an advanced materials manufacturing company developing and commercializing two proprietary nanotechnologies exclusively licensed from Clemson University. Selah Dots™ are patent-pending photoluminescent carbon-based nanoparticles. Selah Tubes™ are enriched single-walled nanotubes with precisely engineered electronic properties protected under US Patent No. 7,374,685.Our mission is to consistently deliver high quality nanomaterials and nano-enabled products to the global marketplace. Our growth strategy is to leverage relationships with market leading companies to establish mutually beneficial joint research and development agreements. Our strategy is founded in the conviction that early successes in our target markets will occur via exploitation of nanomaterials in established applications in which their incorporation is both useful and compelling, and addresses needs that nanotechnology can fulfill either immediately or in the very short term.In December 2009, Michael sold Selah Technologies to Lab21 Ltd., a multinational diagnostics firm based in Cambridge UK.